Celltrion Pharm Inc
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals a… Read more
Celltrion Pharm Inc (068760) - Net Assets
Latest net assets as of September 2025: ₩426.42 Billion KRW
Based on the latest financial reports, Celltrion Pharm Inc (068760) has net assets worth ₩426.42 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩745.80 Billion) and total liabilities (₩319.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩426.42 Billion |
| % of Total Assets | 57.18% |
| Annual Growth Rate | 9.08% |
| 5-Year Change | 32.06% |
| 10-Year Change | 68.02% |
| Growth Volatility | 14.65 |
Celltrion Pharm Inc - Net Assets Trend (2011–2024)
This chart illustrates how Celltrion Pharm Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Celltrion Pharm Inc (2011–2024)
The table below shows the annual net assets of Celltrion Pharm Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩396.92 Billion | +5.38% |
| 2023-12-31 | ₩376.67 Billion | +5.57% |
| 2022-12-31 | ₩356.79 Billion | +7.48% |
| 2021-12-31 | ₩331.97 Billion | +10.45% |
| 2020-12-31 | ₩300.56 Billion | +7.33% |
| 2019-12-31 | ₩280.03 Billion | +3.70% |
| 2018-12-31 | ₩270.03 Billion | -8.03% |
| 2017-12-31 | ₩293.62 Billion | -14.80% |
| 2016-12-31 | ₩344.65 Billion | +45.89% |
| 2015-12-31 | ₩236.23 Billion | +10.17% |
| 2014-12-31 | ₩214.43 Billion | +27.32% |
| 2013-12-31 | ₩168.41 Billion | +7.10% |
| 2012-12-31 | ₩157.25 Billion | +22.59% |
| 2011-12-31 | ₩128.27 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Celltrion Pharm Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13250487089000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩132.50 Billion | 33.38% |
| Common Stock | ₩272.35 Billion | 68.62% |
| Total Equity | ₩396.92 Billion | 100.00% |
Celltrion Pharm Inc Competitors by Market Cap
The table below lists competitors of Celltrion Pharm Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mach Natural Resources LP
NYSE:MNR
|
$812.07 Million |
|
Sunshine Insurance Group Company Limited
F:E57
|
$812.67 Million |
|
MOLTEN VENTURES LS-01
F:GRW
|
$812.83 Million |
|
LOVISA HLDGS DEF.
F:LO7
|
$812.98 Million |
|
Jointo Energy Investment Co Ltd Hebei
SHE:000600
|
$810.91 Million |
|
Medikaloka Hermina PT
JK:HEAL
|
$810.80 Million |
|
SENSIRION HOLDING
F:1Q3
|
$810.77 Million |
|
Daktronics Inc
NASDAQ:DAKT
|
$810.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Celltrion Pharm Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 376,665,735,600 to 396,921,557,130, a change of 20,255,821,530 (5.4%).
- Net income of 21,966,117,520 contributed positively to equity growth.
- Share repurchases of 4,047,083,050 reduced equity.
- New share issuances of 880,837,380 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩21.97 Billion | +5.53% |
| Share Repurchases | ₩4.05 Billion | -1.02% |
| Share Issuances | ₩880.84 Million | +0.22% |
| Other Changes | ₩1.46 Billion | +0.37% |
| Total Change | ₩- | 5.38% |
Book Value vs Market Value Analysis
This analysis compares Celltrion Pharm Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9217.14 | ₩61200.00 | x |
| 2017-12-31 | ₩7829.62 | ₩61200.00 | x |
| 2018-12-31 | ₩7190.64 | ₩61200.00 | x |
| 2019-12-31 | ₩7451.76 | ₩61200.00 | x |
| 2020-12-31 | ₩7997.82 | ₩61200.00 | x |
| 2021-12-31 | ₩8415.26 | ₩61200.00 | x |
| 2022-12-31 | ₩8201.30 | ₩61200.00 | x |
| 2023-12-31 | ₩8661.73 | ₩61200.00 | x |
| 2024-12-31 | ₩9132.28 | ₩61200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Celltrion Pharm Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.53%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.60%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 1.69x
- Recent ROE (5.53%) is above the historical average (3.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 2.68% | 7.39% | 0.22x | 1.68x | ₩-9.39 Billion |
| 2012 | 2.26% | 7.56% | 0.14x | 2.11x | ₩-12.17 Billion |
| 2013 | 1.55% | 4.96% | 0.15x | 2.15x | ₩-14.23 Billion |
| 2014 | 2.74% | 8.79% | 0.16x | 1.92x | ₩-15.57 Billion |
| 2015 | 2.85% | 9.01% | 0.16x | 1.98x | ₩-16.89 Billion |
| 2016 | 0.85% | 2.78% | 0.21x | 1.48x | ₩-31.55 Billion |
| 2017 | 0.92% | 2.00% | 0.29x | 1.60x | ₩-26.65 Billion |
| 2018 | -3.48% | -6.39% | 0.32x | 1.68x | ₩-36.39 Billion |
| 2019 | 3.07% | 4.96% | 0.37x | 1.68x | ₩-19.40 Billion |
| 2020 | 6.97% | 8.97% | 0.43x | 1.82x | ₩-9.12 Billion |
| 2021 | 10.42% | 8.67% | 0.63x | 1.92x | ₩1.38 Billion |
| 2022 | 7.28% | 6.72% | 0.64x | 1.68x | ₩-9.72 Billion |
| 2023 | 5.65% | 5.47% | 0.61x | 1.70x | ₩-16.40 Billion |
| 2024 | 5.53% | 4.60% | 0.71x | 1.69x | ₩-17.73 Billion |
Industry Comparison
This section compares Celltrion Pharm Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Celltrion Pharm Inc (068760) | ₩426.42 Billion | 2.68% | 0.75x | $811.10 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |